Health TrialsbyHealthPanel

Prospective Cohort With Hemopathy in Languedoc-Roussillon

ConditionHematologic Malignancy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Montpellier

About this trial

Prospective Cohort Study of clinical and laboratory data of patients with hemopathy.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age over 18

Consultant or hospitalized patient for suspected malignant hemopathy and justifying further exploration or patient with a diagnosis of malignant hemopathy less than 6 months old at the time of signing the consent

Having signed an informed consent

Affiliated with a social security scheme

Disqualifiers

Minor or major protected

Patients who have received treatment for hematological pathology

Trial population

patient for suspected haematological disease and justifying further exploration

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • hematologic malignancy

    Biological/Vaccine

    hematologic malignancy with a sampling of blood

Treatment groups

500 Participants
are divided into 1 treatment group
Group A: hematologic malignancy1 intervention

Trial outcomes

Primary outcomes

1

Survival with 2 years

Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC\_QLQ-C30

Time frame
2 years

Secondary outcomes

1

Survival with 5 years

Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC\_QLQ-C30

Time frame
5 years
2

Survival with 10 years

Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC\_QLQ-C30

Time frame
10 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital, Montpellier

Lead sponsor

Source ClinicalTrials.gov
Apply now